MTHFR and Methylfolate: What the Evidence Actually Says

Here is the pitch, and you have almost certainly encountered some version of it: You have an MTHFR mutation. Your body can't convert folic acid properly. You need methylfolate instead — the active form, which bypasses the broken enzyme.

It is a compelling pitch, because parts of it are true. The biochemistry it describes is real. Where it goes wrong is in the leap from "this molecule is downstream of the enzyme" to "you personally need to buy this molecule." That leap is where the evidence gets thin and the marketing gets loud.

The biochemistry, stated honestly

Folate comes in several forms, and the distinction matters for understanding the argument.

The MTHFR enzyme's job is to produce 5-MTHF. So yes: if you supplement 5-MTHF directly, you are supplying the enzyme's product, and the enzyme's efficiency becomes irrelevant to that particular step. L-methylfolate does not require MTHFR enzyme conversion, which is why it is proposed as especially useful for people with C677T or A1298C variants.

That is a real mechanism. The question is whether it produces a real clinical benefit for people with these common variants. Mechanism and benefit are not the same thing, and conflating them is the single most common error in supplement marketing.

What the evidence actually shows

Does methylfolate raise folate levels? Yes.

This is well established and not controversial. L-methylfolate supplementation effectively raises circulating folate and effectively lowers homocysteine. It works as a folate supplement. Nobody disputes this.

But note carefully: folic acid also does both of those things, including in people with MTHFR variants. The reduced-activity enzyme is not a wall; it is a slower conveyor belt. Give it more raw material and it produces more product. This is exactly why folic acid fortification worked at a population level despite roughly 40% of that population carrying MTHFR variants.

Is methylfolate superior to folic acid in MTHFR carriers? The evidence is far weaker than the marketing.

This is the claim that actually matters, and it is the one where the evidence base thins out dramatically.

Head-to-head randomised trials are scarce. One randomised, double-blind trial conducted in Tehran compared 5-MTHF against folic acid in women with three or more idiopathic recurrent abortions, stratified by MTHFR C677T and A1298C genotype, with participants taking 1 mg of one or the other from at least eight weeks pre-conception through week 20 of pregnancy. Studies like this are exactly what is needed. But a small number of trials in specific populations does not establish a general recommendation for the tens of millions of people with these variants — and crucially, no major guideline body has been persuaded to change its advice on the basis of them.

What the guideline bodies say

That second point is worth dwelling on. The entire rationale for aggressively lowering homocysteine rests on the assumption that homocysteine causes cardiovascular disease. Large randomised trials of homocysteine-lowering therapy have consistently failed to reduce cardiovascular events. Lowering homocysteine with supplements is achievable; it just does not appear to buy you the outcome the whole theory promised.

Where the marketing overreaches

Some specific claims deserve direct scrutiny.

"Folic acid is bad for MTHFR carriers"

The claim usually goes: unmetabolised folic acid accumulates, blocks folate receptors, and prevents methylfolate uptake. This is a real hypothesis with some laboratory basis, and unmetabolised folic acid in serum is a genuine research topic.

But it has not been established as a clinically meaningful harm at normal supplemental doses, and it sits awkwardly against a large body of population-level evidence: folic acid fortification produced a substantial, well-documented drop in neural tube defects in populations where roughly 40% of people carry MTHFR variants. If folic acid were harmful to those people, that is not the result we would have seen. Every public health authority in the world continues to recommend folic acid for pregnancy, and they do so knowing exactly how common MTHFR variants are.

"Over 50% of people have an MTHFR variant, so most people need methylfolate"

The first half of that sentence is roughly accurate. The second half is a non-sequitur, and the first half is precisely why. A variant that half the population carries and that impairs nothing detectable in a well-fed population is not a deficiency state requiring correction. It is normal human variation.

Turn the argument around: if half the population genuinely could not use the standard, fortified form of folate, that would have been a visible public health catastrophe. It was not.

"Start with high-dose methylfolate"

Doses of 5 mg and above are marketed directly to consumers on the basis of a genotype. High-dose L-methylfolate is a real prescription intervention in specific psychiatric contexts, under clinical supervision. It is not an appropriate self-directed response to a common polymorphism. Notably, even the supplement industry acknowledges that excessive methylfolate can produce adverse effects — anxiety, insomnia, irritability — which they describe as "overmethylation." That an industry warns about its own product's side effects at the doses it recommends should give you pause.

Where methylfolate is genuinely reasonable

To be fair to a genuinely useful compound, there are legitimate contexts:

• As a prescribed medical food in specific psychiatric care. L-methylfolate has an established prescription role as an adjunct in some cases of major depressive disorder, under clinical supervision. This is not the same as buying it off a shelf because of a genotype.
• If you cannot tolerate folic acid or prefer the active form for personal reasons, methylfolate at ordinary supplemental doses (400–800 mcg) is a reasonable alternative folate source. It works. It costs more. That is a fine trade if you want to make it.
• Documented, genuinely elevated homocysteine under clinical management. Here you are treating a measured abnormality, not a genotype.

What we would actually suggest

1. Eat folate-rich food. Spinach, lentils, asparagus, avocado, citrus, liver, fortified grains. This is the foundation and it is not optional.
2. If pregnant or planning pregnancy, take the folic acid dose your provider recommends. Do not modify it based on an MTHFR result. This is explicit guidance and the stakes — neural tube defects — are not the place to freelance.
3. If you are worried, measure homocysteine and folate. Cheap, real, actionable.
4. If you want to take methylfolate anyway, take a normal dose. 400–800 mcg is a reasonable supplemental range. You do not need 5 mg because of a common polymorphism.
5. Be deeply skeptical of multi-supplement "methylation protocols." Complex stacks built on a single common variant, sold by the same people who did the testing, should trigger every alarm you have.

The bottom line

L-methylfolate is a real, bioavailable form of folate that genuinely bypasses the MTHFR enzyme. If you want to take it, it works fine as a folate supplement.

What it is not is a medically necessary correction for a common polymorphism. The guideline bodies have looked at this question and told you not to change your folate dose based on your MTHFR result. The industry built on telling you otherwise has a product to sell, and you are entitled to weigh that fact.